Close

Teva Pharma's (TEVA) TEV-48125 Met Primary, Secondary Endpoints in Migraine Phase 2b

March 23, 2015 8:51 AM EDT Send to a Friend
Teva Pharma (NYSE: TEVA) announced he successful completion of its Phase IIb migraine prevention program with positive top-line results from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login